GURU.Markets stock price, segment price, and overall market index valuation
The company's share price I Mab
I-Mab is a Chinese biotechnology company focused on developing oncology drugs. Its share price reflects both the potential of its research and development and the risks associated with China's regulatory environment and geopolitical tensions.
Share prices of companies in the market segment - General oncology therapy
I-Mab (IMAB) is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative drugs for the treatment of oncological and autoimmune diseases. We classify it as a "General Oncotherapeutics" company. The chart below shows general trends in the global oncology biotechnology sector.
Broad Market Index - GURU.Markets
I-Mab is a global biopharmaceutical company that develops and commercializes innovative drugs for the treatment of oncology. As a component of the GURU.Markets index, it represents the biotech sector. The chart below represents the entire market. See how I-Mab shares compare to the overall trend.
Change in the price of a company, segment, and market as a whole per day
IMAB - Daily change in the company's share price I Mab
Shares of I-Mab, a Chinese biotech company, are highly volatile. Change_co measures market reaction to clinical trial and partnership data. This metric is an essential component in building valuation models for companies operating at the intersection of science and geopolitics on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - General oncology therapy
I-Mab is an oncology company. This chart illustrates the extreme volatility of the biotech sector. Comparing it to IMAB, which focuses on the Chinese market, helps understand its unique regulatory and commercial risks.
Daily change in the price of a broad market stock, index - GURU.Markets
I-Mab is a biopharmaceutical company developing cancer treatments. Oncology is a highly volatile sector driven by clinical trial results. The chart below shows the average fluctuations in this industry, providing context for evaluating I-Mab shares.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization I Mab
For I-Mab, a Chinese biotech company, its year-over-year performance is a story of developing innovative oncology drugs and partnering with Western giants. Its market capitalization change over the past 12 months reflects both progress in its own clinical trials and the success of its partners, such as AbbVie, confirming the value of its scientific platform.
Annual dynamics of market capitalization of the market segment - General oncology therapy
I-Mab is a biotech company focused on developing innovative cancer treatments. It has both its own developments and partnerships. The graph shows how its scientific success, reliance on clinical trial results, and focus on the Chinese market influence its growth.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
I-Mab is a Chinese biotech company whose stock price (ADR) is driven by two factors: the success of its R&D platform and investor sentiment toward the Chinese market. The chart is a complex story, where scientific potential contends with geopolitical and regulatory risks, creating high volatility.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization I Mab
The market capitalization of I-Mab, a biopharmaceutical company, is speculative. Monthly fluctuations on the chart reflect not revenue, but news about the progress of clinical trials of its oncology drugs and partnerships with major pharmaceutical companies.
Monthly dynamics of market capitalization of the market segment - General oncology therapy
The Chinese biotech sector combines the risks of pharmaceutical development with geopolitical uncertainty. Its market capitalization dynamics, shown in the chart, reflect both factors. In this challenging environment, companies like I-Mab are attempting to bring their oncology drugs to the global market.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
I-Mab, a biotech company focused on oncology, moves to the rhythm of drug development news. Its shares can surge or plummet, defying overall market trends. The chart demonstrates this independence.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization I Mab
I-Mab, a global biopharmaceutical company focused on oncology, is influenced by both scientific and geopolitical factors. Its weekly stock price reflects news about clinical trials, partnerships with major pharma, and US-China biotech relations.
Weekly dynamics of market capitalization of the market segment - General oncology therapy
Biopharmaceutical companies operating in the Chinese market, like I-Mab, are subject to common regulatory risks and the specifics of the Chinese healthcare system. The chart below reflects these factors and allows for a comparison of I-Mab's success in developing innovative drugs compared to other Chinese biotech companies.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
I-Mab is a Chinese biotech company focused on oncology. Its shares are exposed to both biotech risks and China's geopolitical risks. The chart clearly shows how these unique factors cause its stock to move completely independently of global markets.
Market capitalization of the company, segment and market as a whole
IMAB - Market capitalization of the company I Mab
I-Mab's market capitalization chart represents investors' valuation of its portfolio of oncology drugs developed for the Chinese and global markets. Its sharp decline from its peaks reflects both the general correction in biotech and specific setbacks in its clinical programs. Its current value is a valuation of its remaining assets and partnerships.
IMAB - Share of the company's market capitalization I Mab within the market segment - General oncology therapy
I-Mab is a biopharmaceutical company developing innovative cancer treatments, focusing on the Chinese and US markets. Its market capitalization in the general oncology sector reflects the potential of its extensive drug portfolio. The company's market weight reflects its ambition to become a bridge between Western and Eastern innovations in the fight against cancer.
Market capitalization of the market segment - General oncology therapy
This chart shows the total market capitalization of the entire oncology sector. For I-Mab, a biopharmaceutical company building a bridge between China and the West, this line is a map of global science. The chart's growth reflects the trillions of dollars invested in the fight against cancer and demonstrates the vast and competitive landscape in which the company is attempting to commercialize its innovative drugs.
Market capitalization of all companies included in a broad market index - GURU.Markets
I-Mab is a biopharmaceutical company focused on developing oncology drugs for the global market. Its global market capitalization reflects China's growing ambitions in the global pharmaceutical industry. It represents a significant share of Asian innovation in the fight against cancer.
Book value capitalization of the company, segment and market as a whole
IMAB - Book value capitalization of the company I Mab
I-Mab is a global biopharmaceutical company developing innovative cancer treatments. Its book value is determined by its financial resources and scientific base. This includes significant cash reserves for clinical trials worldwide. How has this capital changed? The chart below shows.
IMAB - Share of the company's book capitalization I Mab within the market segment - General oncology therapy
I-Mab is a global biotech company with roots in China. It is actively investing in building its own infrastructure, including modern R&D centers and manufacturing facilities for the production of innovative oncology drugs. The chart shows its growing share of the physical infrastructure required for the global biopharmaceutical industry.
Market segment balance sheet capitalization - General oncology therapy
I-Mab, a biopharmaceutical company, has a capital-intensive R&D business. This requires the ownership of advanced laboratories in China and the United States. The BCap_Seg chart for the biotech sector shows that creating globally competitive drugs requires a robust scientific infrastructure.
Book value of all companies included in the broad market index - GURU.Markets
I-Mab's balance sheet includes its cutting-edge research laboratories in China and the US, as well as an extensive portfolio of patents for innovative cancer treatments. The company's assets represent its global scientific and intellectual capital. The chart below shows how this R&D-focused biotech stacks up against traditional pharma.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - I Mab
I-Mab's balance sheet represents its R&D capital. Its market value, which is below book value, reflects geopolitical risks and investor concerns about biotech companies with Chinese roots, despite its strong development pipeline. The chart represents a geopolitical discount.
Market to book capitalization ratio in a market segment - General oncology therapy
I-Mab is a biotech company developing innovative cancer treatments. Its high valuation on this chart reflects its strong scientific pipeline and potential partnerships with major pharmaceutical companies that can validate the value of its developments.
Market to book capitalization ratio for the market as a whole
I-Mab is a biotech company focused on developing innovative cancer treatments. Its value lies in its scientific platform and clinical pipeline. Its market capitalization is a multiple of its book value, reflecting its promise of developing new, effective oncology treatments.
Debts of the company, segment and market as a whole
IMAB - Company debts I Mab
I-Mab, a biotech company focused on developing oncology drugs for the global market, uses capital to conduct numerous clinical trials. This chart shows how the company funds its extensive and expensive R&D pipeline, aiming to develop new cancer treatments through partnerships and in-house development.
Market segment debts - General oncology therapy
I-Mab is a clinical-stage biotech focused on developing oncology drugs. Like its peers in the sector, the company has limited revenue and funds its expensive research through equity and partnerships. This chart illustrates the industry's typical financial model, with minimal debt.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio I Mab
I-Mab is a biopharmaceutical company developing innovative cancer treatments. Its operations require significant investment in R&D. This chart illustrates the company's reliance on external capital to fund its expensive research. It highlights the high risk and potential inherent in companies at the forefront of oncology.
Market segment debt to market segment book capitalization - General oncology therapy
I-Mab is a biopharmaceutical company focused on developing innovative cancer treatments. It has both global and Chinese programs. The chart illustrates how aggressively the biotech sector uses debt to fund R&D, providing context for assessing I-Mab's capital-intensive strategy in two key markets.
Debt to book value of all companies in the market
I-Mab, a biopharmaceutical company focused on oncology, is actively pursuing clinical development both in China and globally, requiring significant investment. This chart shows the overall debt burden in the market. It helps assess how aggressively the company is using capital to accelerate its drug delivery compared to other biotechs.
P/E of the company, segment and market as a whole
P/E - I Mab
I-Mab is a clinical-stage biopharmaceutical company focused on developing innovative treatments for oncology and autoimmune diseases. This chart shows how the market values its development pipeline. This value is based on progress in clinical trials and the success of partnerships with major global pharmaceutical companies.
P/E of the market segment - General oncology therapy
I-Mab is a biotech company focused on oncology. This chart shows the average valuation for the biotech sector. It serves as a backdrop for I-Mab's valuation: investors look not at its profits relative to the industry, but at the potential of its drug pipeline and partnerships, which justify its valuation.
P/E of the market as a whole
I-Mab is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative oncology therapeutics. This chart reflects the overall risk appetite of investors in the biotech sector. It helps understand whether I-Mab's valuation is based on the potential of its pipeline or whether it moves in tandem with overall industry sentiment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company I Mab
I-Mab is a biotechnology company focused on developing innovative cancer treatments. Future profits depend on the success of its clinical programs and partnerships with major pharmaceutical companies. This chart reflects market expectations regarding the potential of its scientific developments in the global fight against cancer.
%20P%2FE%20I%20Mab&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-I-Mab&v=1772513481222 "Chart of the company's future (projected) P/E I Mab")
Future (projected) P/E of the market segment - General oncology therapy
I-Mab is a global biotechnology company focused on the discovery, development, and commercialization of innovative therapeutics for the treatment of oncology diseases. The data here reflects the analysts' collective bet on the success of its diversified pipeline of developments, both proprietary and in partnership with other companies.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-General-oncology-therapy&v=1772513481245 "Future (projected) P/E graph of the market segment - General oncology therapy")
Future (projected) P/E of the market as a whole
I-Mab is a biotech company developing innovative cancer treatments, focusing on China and the global market. This general sentiment chart shows how willing investors are to invest in global biotech companies with strategies spanning both developed and emerging markets.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513481295 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit I Mab
I-Mab is a biotech company focused on developing innovative drugs for the treatment of oncology and autoimmune diseases. This graph shows its path from research to potential commercialization. It reflects expenditures on global clinical trials and partnerships with major pharmaceutical companies.
Profit of companies in the market segment - General oncology therapy
I-Mab is a biopharmaceutical company focused on developing innovative drugs for the treatment of cancer and autoimmune diseases. The company has a strong presence both in China and globally. Its success in clinical development and partnerships with major pharmaceutical companies determine its potential profitability and contribution to the oncology sector.
Overall market profit
I-Mab is a biotech company focused on developing innovative cancer treatments. Its success depends on the results of clinical trials and partnerships. The overall economic situation, reflected in this chart, does not affect the demand for its drugs, but it does impact the financial markets on which its costly operations are financed.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company I Mab
I-Mab is a biotechnology company focused on developing innovative drugs for the treatment of oncology and autoimmune diseases. This chart shows analysts' speculative expectations. Future profits depend on the success of clinical trials, conducted both independently and in partnership with global pharmaceutical companies.
%20profit%20of%20the%20company%20I%20Mab&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-I-Mab&v=1772513481404 "Graph of future (projected) profit of the company I Mab")
Future (predicted) profit of companies in the market segment - General oncology therapy
I-Mab is a biotech company focused on developing innovative drugs for the treatment of cancer and autoimmune diseases. The profitability forecasts for the oncology sector, shown in the graph, highlight the enormous potential and competition. This chart provides context for assessing the potential success of I-Mab's development pipeline in the global market.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-General-oncology-therapy&v=1772513481444 "Graph of future (predicted) profits of companies in a market segment - General oncology therapy")
Future (predicted) profit of the market as a whole
I-Mab is a biotech company focused on developing innovative cancer treatments. Like many companies in this sector, it relies on successful clinical trials and partnerships. The favorable economic environment, reflected in this chart, improves the investment climate and facilitates funding for R&D.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513481453 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - I Mab
I-Mab is a global biopharmaceutical company focused on developing innovative treatments for oncology and autoimmune diseases. Its revenue may not be stable. This chart shows how investors view its extensive pipeline and strategic partnerships with major pharmaceutical companies.
P/S market segment - General oncology therapy
I-Mab is a global biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of oncology diseases. This metric reflects the average revenue estimate in the biotech sector and helps assess how investors perceive the company's oncology pipeline and its global ambitions.
P/S of the market as a whole
I-Mab is a global biopharmaceutical company focused on developing innovative cancer treatments. The company has a pipeline of developments in various stages of clinical trials. This chart provides context for understanding how investors value companies based on existing revenues, which is important when analyzing biotech companies whose revenue depends on successful R&D.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company I Mab
I-Mab is a global biotechnology company focused on developing innovative cancer treatments. This chart reflects investors' high valuation of its potential future revenue. This valuation is based on their belief in its extensive clinical development pipeline and strategic partnerships with major pharmaceutical companies.
%20P%2FS%20I%20Mab&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-I-Mab&v=1772513481631 "The graph of the company's future (projected) P/S I Mab")
Future (projected) P/S of the market segment - General oncology therapy
I-Mab is a global biopharmaceutical company focused on developing innovative treatments for oncology and autoimmune diseases. This chart compares market expectations for its future revenue with those of other oncology companies. This valuation reflects investor confidence in its broad and promising clinical pipeline.
%20P%2FS%20market%20segment%20graph%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-General-oncology-therapy&v=1772513481665 "Future (projected) P/S market segment graph - General oncology therapy")
Future (projected) P/S of the market as a whole
I-Mab is a biotech company focused on developing innovative cancer treatments, with a focus on China and the global market. Its value is determined by progress in clinical trials. This chart of overall market expectations is merely a backdrop for I-Mab, as its success depends on scientific data and partnerships, not on general economic trends.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513481708 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales I Mab
This chart shows the revenue of I-Mab, a biotechnology company focused on developing innovative drugs for the treatment of oncology and autoimmune diseases. Being in the clinical stage, the company may generate revenue from upfront and milestone payments under its numerous partnerships with major global pharmaceutical companies, as reflected in the chart.
Sales of companies in the market segment - General oncology therapy
I-Mab is a global clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative cancer treatments. This chart shows revenue in the general oncology segment. It reflects the significant investment and scientific progress in cancer treatment, where I-Mab strives to build a portfolio of breakthrough drugs.
Overall market sales
I-Mab is a biotechnology company focused on developing innovative cancer treatments. The company's success depends on its scientific advances and clinical trial results. The overall economic situation, shown in this chart, influences the overall investment climate in the biotechnology sector, which affects I-Mab's ability to fund its research.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company I Mab
I-Mab is a global clinical-stage biotechnology company focused on developing innovative cancer treatments. This projected revenue chart reflects expectations for its extensive pipeline. Growth depends on analysts' confidence in the successful advancement of its drugs through clinical trials and new partnerships.
%20sales%20of%20the%20company%20I%20Mab&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-I-Mab&v=1772513481768 "Schedule of future (projected) sales of the company I Mab")
Future (projected) sales of companies in the market segment - General oncology therapy
I-Mab is a clinical-stage biopharmaceutical company focused on developing innovative treatments for oncology and autoimmune diseases. The company has a strong presence in China and global ambitions. This chart shows projected revenue for the overall oncology therapeutics sector, reflecting the global search for new cancer drugs.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-General-oncology-therapy&v=1772513481773 "Schedule of future (projected) sales of companies in the market segment - General oncology therapy")
Future (projected) sales of the market as a whole
I-Mab is a biotechnology company developing innovative cancer treatments. Its future depends entirely on success in clinical trials. A positive economic environment and market sentiment impact its ability to attract capital and partner with major pharmaceutical companies to finance its development.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513481792 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality I Mab
I-Mab is a global biotech company developing innovative cancer treatments. Currently in the clinical stage, it is actively investing in its extensive pipeline of candidates. This chart reflects the cost of these ambitions, demonstrating the R&D expenditures required to compete in the global oncology market.
Market segment marginality - General oncology therapy
I-Mab is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative drugs for the treatment of oncology. This chart reflects its financial performance. For a company with a broad pipeline, outperforming competitors in terms of profitability may be due to major licensing agreements with Western pharmaceutical giants.
Market marginality as a whole
I-Mab is a biotech company focused on developing innovative cancer treatments. Its success depends entirely on the results of clinical trials and strategic partnerships, not on the overall economic performance reflected in this chart. A breakthrough in oncology can transform the company, regardless of the broader market situation.
Employees in the company, segment and market as a whole
Number of employees in the company I Mab
I-Mab is a biotechnology company focused on developing innovative oncology drugs for the global market. This graph shows the team's scientists. The staff dynamics reflect both the progress of its own research and the strategic partnerships with major pharmaceutical companies that are a key part of its business model.
Share of the company's employees I Mab within the market segment - General oncology therapy
I-Mab is a biotech company developing innovative cancer treatments. With global ambitions, it invests in a team of scientists and clinicians to conduct research worldwide. This chart illustrates its growing scale, reflecting its share of the talent pool working at the forefront of global oncology.
Number of employees in the market segment - General oncology therapy
I-Mab is a Chinese biotech company focused on developing innovative oncology drugs for the global market. This chart illustrates the growth and ambitions of the Chinese biotech. The rapid expansion of its scientific and clinical staff reflects both significant investments in R&D and a strategy to conduct clinical trials simultaneously in China and the West.
Number of employees in the market as a whole
I-Mab is an international biotech company developing innovative cancer treatments. Its teams are located in both China and the United States. This graph offers insight into the globalization of science and pharmaceuticals, where international teams work on common problems, and hiring trends reflect research progress rather than local economic conditions.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company I Mab (IMAB)
I-Mab is a global biotech company focused on the discovery, development, and commercialization of innovative cancer treatments. This chart shows the enormous market value per scientist. This is a classic example of biotech investors evaluating scientific potential and development pipeline rather than current financial performance.
%20of%20the%20company%20I%20Mab%20(IMAB)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-I-Mab-IMAB&v=1772513481872 "Chart of market capitalization per employee (in thousands of dollars) of the company I Mab (IMAB)")
Market capitalization per employee (in thousands of dollars) in the market segment - General oncology therapy
I-Mab is a biopharmaceutical company developing innovative cancer treatments. In the global race to develop new oncology drugs, this chart reflects investor confidence in their research pipeline. Their high per-employee cost suggests that the market values the potential of their developments and their ability to compete globally.
%20by%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-General-oncology-therapy&v=1772513481908 "Market capitalization per employee (in thousands of dollars) by market segment - General oncology therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
I-Mab is a biopharmaceutical company developing innovative cancer treatments. This metric reflects a business at the forefront of oncology. Its market capitalization is based on the potential of its developments. The team's efforts can lead to the creation of a breakthrough treatment, which is valued by the market.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513481925 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company I Mab (IMAB)
I-Mab is a biotech company (China/USA) focused on immuno-oncology. They are in the clinical stage but have partnerships. They may not have sales revenue, but may have milestone payments. This chart shows their financial position. Most often, it's a loss per employee (R&D costs).
%20Chart%20I%20Mab%20(IMAB)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-I-Mab-IMAB&v=1772513481929 "Company Profit Per Employee (in thousands of dollars) Chart I Mab (IMAB)")
Profit per employee (in thousands of dollars) in the market segment - General oncology therapy
I-Mab is a Chinese biotech company developing innovative cancer treatments. While in the clinical stage, it is not profitable. This metric reflects the R&D budget burn per employee, which is comparable to global industry standards for capital-intensive oncology research.
%20in%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-General-oncology-therapy&v=1772513481930 "Chart of profit per employee (in thousands of dollars) in the market segment - General oncology therapy")
Profit per employee (in thousands of dollars) for the market as a whole
I-Mab is a global biotech company focused on developing clinical-stage oncology and immune-based treatments. This chart shows the company's negative return on employee (ROE)—the cost of R&D. It reflects how much capital the company spends on its scientific team to validate and develop its portfolio of innovative cancer treatments.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513481932 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee I Mab (IMAB)
I-Mab is a biopharmaceutical company focused on developing innovative cancer treatments. This graph is typical for a clinical-stage company. Low or no revenue per employee is normal for a company investing in a broad portfolio of potential oncology drugs.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-I-Mab-IMAB&v=1772513481966 "Sales chart per company employee I Mab (IMAB)")
Sales per employee in the market segment - General oncology therapy
I-Mab (IMAB) is a Chinese biotech company focused on developing innovative cancer treatments (immunotherapy). This chart shows the revenue (primarily from partnerships with Western pharmaceutical companies) generated by each employee (scientist). This is an indicator of the productivity of their R&D platform and its value to the global pharmaceutical market.
Sales per employee for the market as a whole
I-Mab (IMAB) is a Chinese biopharmaceutical company developing innovative oncology drugs. They operate both in China and globally. Their R&D business reflects their success in securing partnerships (such as with AbbVie), which generate upfront and milestone payments generated by their research team.
Short shares by company, segment and market as a whole
Shares shorted by company I Mab (IMAB)
I-Mab is a Chinese biotech company developing oncology drugs. This chart shows bearish bets. Bears are betting on dual risks: a high probability of clinical trial failure and geopolitical tensions that could hinder the company's entry into global markets or raising capital.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-I-Mab-IMAB&v=1772513481997 "Short Shares Chart for the Company I Mab (IMAB)")
Shares shorted by market segment - General oncology therapy
I-Mab is a biotech company (China/US) focused on developing immuno-oncology drugs. This chart shows short bets. "Shorts" here are bets that their clinical trials will fail or that geopolitical tensions (US-China) will hinder their business.
Shares shorted by the overall market
I-Mab is a Chinese biotech company focused on developing innovative cancer treatments. This chart shows the overall level of fear. In moments of panic, investors often apply a "double discount" to such companies: first, they're a biotech without profits, and second, they're a Chinese stock. This makes them extremely vulnerable to sell-offs.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator I Mab (IMAB)
I-Mab (IMAB) is a Chinese biotech company focused on developing innovative drugs in oncology and autoimmune diseases for the global market. This chart measures hype. It shows "overheated" (above 70) due to partnership news (e.g., with AbbVie) or "oversold" (below 30) due to geopolitical risks or R&D setbacks.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-I-Mab-IMAB&v=1772513482032 "RSI 14 indicator chart for the company's stock I Mab (IMAB)")
RSI 14 Market Segment - General oncology therapy
I-Mab (IMAB) is a Chinese biotech and cancer "hunter." They develop innovative (not "copycats") immuno-oncology drugs. The RSI_14_Seg for "Oncology" (biotech) shows the overall sentiment. The chart helps us understand: is IMAB's volatility due to their R&D, or is the entire sector overheated (or oversold)?
RSI 14 for the overall market
I-Mab (IMAB) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast IMAB (I Mab)
I-Mab is a Chinese biotech company developing innovative drugs for the treatment of cancer (immuno-oncology) and autoimmune diseases. This chart shows the average 12-month analyst forecast. Their target price reflects their assessment of the potential of their R&D platform and the risks associated with partnerships and geopolitics.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-IMAB-I-Mab&v=1772513482068 "A chart showing analyst consensus forecasts for the expected stock price. IMAB (I Mab)")
The difference between the consensus estimate and the actual stock price IMAB (I Mab)
I-Mab is a Chinese biotech company developing a portfolio of innovative immuno-oncology drugs. This chart shows how the current share price differs from the "fair" value predicted by analysts. It reflects their faith in the company's scientific platform and its partnerships with Big Pharma.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-IMAB-I-Mab&v=1772513482069 "A chart showing the difference between the consensus forecast and the actual stock price. IMAB (I Mab)")
Analyst consensus forecast for stock prices by market segment - General oncology therapy
I-Mab is a Chinese biotech company focused on developing innovative immuno-oncology drugs for the global market. This chart shows analysts' overall expectations for the general oncology sector. It reflects whether experts believe in the ability of Chinese R&D centers to create global blockbusters.
Analysts' consensus forecast for the overall market share price
I-Mab is a Chinese biotech company specializing in the development of innovative immuno-oncology drugs. This chart shows overall risk appetite. For I-Mab, operating in a high-risk sector and in a geopolitically sensitive jurisdiction (China), overall market optimism is important, but investors weigh it against specific regional risks.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index I Mab
I-Mab (IMAB) is a Chinese biotech company focused on developing innovative immuno-oncology and autoimmune disease therapeutics for the global market. This chart is a summary assessment. It reflects not only their scientific R&D potential but also the high geopolitical risks (US-China relations) that influence the valuation of Chinese biotech companies.
AKIMA Market Segment Index - General oncology therapy
I-Mab (IMAB) is a globally active Chinese biotech innovator focused on immuno-oncology. The company is developing a portfolio of breakthrough antibodies (for cancer treatment) that it licenses to giants (AbbVie). This summary metric evaluates R&D. The graph shows the segment average. This benchmark: how does this R&D platform (IMAB) differentiate itself from the average pharma company?
The AKIM Index for the overall market
I-Mab is a biopharmaceutical company with roots in China but focused on the global development of immuno-oncology drugs. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this company, which is transforming into an American biotech company, stacks up against overall economic trends.
